Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review. (1st January 2020)

• Record Type: Journal Article
• Authors: Van de Sande, Leen; Cosyns, Sarah; Willaert, Wouter; Ceelen, Wim
• Is Part Of: Drug delivery. Volume 27:Number 1(2020)
• Page Start: 40
• Page End: 53
• Publication Date: 2020-01-01
• Subjects: Albumin -- intraperitoneal delivery -- peritoneal metastasis -- chemotherapy -- peritoneum; Drug delivery systems -- Periodicals; Drug targeting -- Periodicals; 615.05
• DOI: 10.1080/10717544.2019.1704945
• Languages: English
• ISSNs: 1071-7544

Abstract

Abstract: Albumin is a remarkable carrier protein with multiple cellular receptor and ligand binding sites, which are able to bind and transport numerous endogenous and exogenous compounds. The development of albumin-bound drugs is gaining increased importance in the targeted delivery of cancer therapy. Intraperitoneal (IP) drug delivery represents an attractive strategy for the local treatment of peritoneal metastasis (PM). PM is characterized by the presence of widespread metastatic tumor nodules on the peritoneum, mostly originating from gastro-intestinal or gynaecological cancers. Albumin as a carrier for chemotherapy holds considerable promise for IP delivery in patients with PM. Data from recent (pre)clinical trials suggest that IP albumin-bound chemotherapy may result in superior efficacy in the treatment of PM compared to standard chemotherapy formulations. Here, we review the evidence on albumin-bound chemotherapy with a focus on IP administration and its efficacy in PM.